GB0707034D0 - Compounds - Google Patents

Compounds

Info

Publication number
GB0707034D0
GB0707034D0 GBGB0707034.5A GB0707034A GB0707034D0 GB 0707034 D0 GB0707034 D0 GB 0707034D0 GB 0707034 A GB0707034 A GB 0707034A GB 0707034 D0 GB0707034 D0 GB 0707034D0
Authority
GB
United Kingdom
Prior art keywords
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0707034.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ST ANDREWS
University of Bradford
Original Assignee
ST ANDREWS
University of Bradford
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ST ANDREWS, University of Bradford filed Critical ST ANDREWS
Priority to GBGB0707034.5A priority Critical patent/GB0707034D0/en
Publication of GB0707034D0 publication Critical patent/GB0707034D0/en
Priority to SI200831959T priority patent/SI2481429T1/en
Priority to DK12160565.3T priority patent/DK2481429T3/en
Priority to PT121605653T priority patent/PT2481429T/pt
Priority to ES12160556.2T priority patent/ES2573682T3/es
Priority to HUE12160556A priority patent/HUE029080T2/en
Priority to HUE08718877A priority patent/HUE027528T2/en
Priority to EP12160556.2A priority patent/EP2481428B1/en
Priority to TR2018/07811T priority patent/TR201807811T4/tr
Priority to HUE12160565A priority patent/HUE038633T2/hu
Priority to PL12160565T priority patent/PL2481429T3/pl
Priority to US12/595,482 priority patent/US8691751B2/en
Priority to EP08718877.7A priority patent/EP2134372B1/en
Priority to ES12160565.3T priority patent/ES2683168T3/es
Priority to ES08718877.7T priority patent/ES2573228T3/es
Priority to EP18156526.8A priority patent/EP3348282A1/en
Priority to PL12160556.2T priority patent/PL2481428T3/pl
Priority to PL08718877.7T priority patent/PL2134372T3/pl
Priority to DK12160556.2T priority patent/DK2481428T3/en
Priority to PCT/GB2008/001043 priority patent/WO2008125800A2/en
Priority to LTEP12160565.3T priority patent/LT2481429T/lt
Priority to DK08718877.7T priority patent/DK2134372T3/en
Priority to JP2010502559A priority patent/JP5537413B2/ja
Priority to EP12160565.3A priority patent/EP2481429B1/en
Priority to HK13101399.0A priority patent/HK1174534B/en
Priority to US14/109,333 priority patent/US9358303B2/en
Priority to JP2014090990A priority patent/JP5911908B2/ja
Priority to JP2014090991A priority patent/JP5931952B2/ja
Priority to JP2016088836A priority patent/JP6170590B2/ja
Priority to US15/148,368 priority patent/US9956296B2/en
Priority to US15/923,564 priority patent/US10556014B2/en
Priority to CY20181100663T priority patent/CY1120368T1/el
Priority to HRP20181043TT priority patent/HRP20181043T1/hr
Priority to HK19100772.3A priority patent/HK1258466A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
GBGB0707034.5A 2007-04-12 2007-04-12 Compounds Ceased GB0707034D0 (en)

Priority Applications (34)

Application Number Priority Date Filing Date Title
GBGB0707034.5A GB0707034D0 (en) 2007-04-12 2007-04-12 Compounds
EP12160565.3A EP2481429B1 (en) 2007-04-12 2008-03-27 MMP-14 specific cleavage sequence
PL12160556.2T PL2481428T3 (pl) 2007-04-12 2008-03-27 Środki niszczące naczynia aktywowane przez mmp
PL08718877.7T PL2134372T3 (pl) 2007-04-12 2008-03-27 Środki niszczące naczynia aktywowane przez mmp
PT121605653T PT2481429T (pt) 2007-04-12 2008-03-27 Sequência de clivagem específica de mmp-14
ES12160556.2T ES2573682T3 (es) 2007-04-12 2008-03-27 Agentes de interrupción vascular activados por MMP
HUE12160556A HUE029080T2 (en) 2007-04-12 2008-03-27 MMP activated vascular disrupting agents
HUE08718877A HUE027528T2 (en) 2007-04-12 2008-03-27 MMP-activated vascular disorders
EP12160556.2A EP2481428B1 (en) 2007-04-12 2008-03-27 MMP activated vascular disrupting agents
TR2018/07811T TR201807811T4 (tr) 2007-04-12 2008-03-27 Bileşikler.
HUE12160565A HUE038633T2 (hu) 2007-04-12 2008-03-27 MMP-14 specifikus hasítási szekvencia
PL12160565T PL2481429T3 (pl) 2007-04-12 2008-03-27 Sekwencja cięcia specyficzna dla mmp-14
PCT/GB2008/001043 WO2008125800A2 (en) 2007-04-12 2008-03-27 Mmp activated vascular disrupting agents
EP08718877.7A EP2134372B1 (en) 2007-04-12 2008-03-27 Mmp activated vascular disrupting agents
ES12160565.3T ES2683168T3 (es) 2007-04-12 2008-03-27 Secuencia de escisión específica de MMP-14
ES08718877.7T ES2573228T3 (es) 2007-04-12 2008-03-27 Agentes disruptores vasculares activados por MMP
EP18156526.8A EP3348282A1 (en) 2007-04-12 2008-03-27 Mmp activated vascular disrupting agents
SI200831959T SI2481429T1 (en) 2007-04-12 2008-03-27 MMP-14 specific cleavage sequence
DK12160556.2T DK2481428T3 (en) 2007-04-12 2008-03-27 MMP-ACTIVATED vascular damaging FUNDS
DK12160565.3T DK2481429T3 (en) 2007-04-12 2008-03-27 MMP-14-SPECIFIC DIVISION SEQUENCE
US12/595,482 US8691751B2 (en) 2007-04-12 2008-03-27 Compounds containing a vascular disrupting agent
LTEP12160565.3T LT2481429T (lt) 2007-04-12 2008-03-27 Specifinė mmp-14 skaldymo seka
DK08718877.7T DK2134372T3 (en) 2007-04-12 2008-03-27 MMP-activated vascular damaging agents
JP2010502559A JP5537413B2 (ja) 2007-04-12 2008-03-27 化合物
HK13101399.0A HK1174534B (en) 2007-04-12 2013-01-31 Mmp activated vascular disrupting agents
US14/109,333 US9358303B2 (en) 2007-04-12 2013-12-17 Compounds containing a vascular disrupting agent
JP2014090990A JP5911908B2 (ja) 2007-04-12 2014-04-25 化合物
JP2014090991A JP5931952B2 (ja) 2007-04-12 2014-04-25 化合物
JP2016088836A JP6170590B2 (ja) 2007-04-12 2016-04-27 化合物
US15/148,368 US9956296B2 (en) 2007-04-12 2016-05-06 Compounds containing a vascular disrupting agent
US15/923,564 US10556014B2 (en) 2007-04-12 2018-03-16 Compounds containing a vascular disrupting agent
CY20181100663T CY1120368T1 (el) 2007-04-12 2018-06-27 Αλληλουχια ειδικης διασπασης μμρ-14
HRP20181043TT HRP20181043T1 (hr) 2007-04-12 2018-07-05 Slijed cijepanja specifičan za mmp-14
HK19100772.3A HK1258466A1 (en) 2007-04-12 2019-01-16 Mmp activated vascular disrupting agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0707034.5A GB0707034D0 (en) 2007-04-12 2007-04-12 Compounds

Publications (1)

Publication Number Publication Date
GB0707034D0 true GB0707034D0 (en) 2007-05-23

Family

ID=38116587

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0707034.5A Ceased GB0707034D0 (en) 2007-04-12 2007-04-12 Compounds

Country Status (16)

Country Link
US (4) US8691751B2 (cg-RX-API-DMAC10.html)
EP (4) EP2134372B1 (cg-RX-API-DMAC10.html)
JP (4) JP5537413B2 (cg-RX-API-DMAC10.html)
CY (1) CY1120368T1 (cg-RX-API-DMAC10.html)
DK (3) DK2134372T3 (cg-RX-API-DMAC10.html)
ES (3) ES2573228T3 (cg-RX-API-DMAC10.html)
GB (1) GB0707034D0 (cg-RX-API-DMAC10.html)
HK (1) HK1258466A1 (cg-RX-API-DMAC10.html)
HR (1) HRP20181043T1 (cg-RX-API-DMAC10.html)
HU (3) HUE027528T2 (cg-RX-API-DMAC10.html)
LT (1) LT2481429T (cg-RX-API-DMAC10.html)
PL (3) PL2481429T3 (cg-RX-API-DMAC10.html)
PT (1) PT2481429T (cg-RX-API-DMAC10.html)
SI (1) SI2481429T1 (cg-RX-API-DMAC10.html)
TR (1) TR201807811T4 (cg-RX-API-DMAC10.html)
WO (1) WO2008125800A2 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0707034D0 (en) 2007-04-12 2007-05-23 St Andrews The Compounds
GB0819287D0 (en) * 2008-10-22 2008-11-26 Univ Bradford Compounds
GB2516882A (en) * 2013-08-02 2015-02-11 Univ Bradford Tumour-targeted theranostic
US9169337B2 (en) 2014-03-12 2015-10-27 Chevron Phillips Chemical Company Lp Polymers with improved ESCR for blow molding applications
NZ731185A (en) * 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
GB2545169B (en) * 2015-12-01 2019-10-09 Ellipses Pharma Ltd Taxane Prodrug Comprising A Membrane Type Matrix Metalloproteinase Cleavage Site
AU2018297614B2 (en) 2017-07-07 2024-04-04 Katholieke Universiteit Leuven Treatment of avascular or hypovascular micro-tumors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4583601A (en) * 2000-03-15 2001-09-24 Du Pont Pharm Co Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use
GB0018240D0 (en) * 2000-07-25 2000-09-13 Pharmacia & Upjohn Spa Polymeric conjugates of antitumor agents
GB0105929D0 (en) * 2001-03-09 2001-04-25 Btg Int Ltd Physiologically activated prodrugs
ES2369542T3 (es) 2002-07-31 2011-12-01 Seattle Genetics, Inc. Conjugados de auristatina y su uso para tratar cáncer, una enfermedad autoinmune o una enfermedad infecciosa.
US20050106100A1 (en) * 2003-09-03 2005-05-19 Harris Thomas D. Compounds containing matrix metalloproteinase substrates and methods of their use
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
CA2591914C (en) 2005-01-24 2017-04-25 Board Of Regents, The University Of Texas System Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
US20090022782A1 (en) 2005-02-25 2009-01-22 National University Corp. Hokkaido University Blood Retainable Device Exhibiting Selective Degradability in Tumor Tissue
US7714016B2 (en) * 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
GB0707034D0 (en) 2007-04-12 2007-05-23 St Andrews The Compounds
GB0819287D0 (en) 2008-10-22 2008-11-26 Univ Bradford Compounds
GB2516882A (en) 2013-08-02 2015-02-11 Univ Bradford Tumour-targeted theranostic

Also Published As

Publication number Publication date
ES2683168T3 (es) 2018-09-25
HUE029080T2 (en) 2017-01-30
EP2481428A3 (en) 2013-07-24
JP5911908B2 (ja) 2016-04-27
JP2014196304A (ja) 2014-10-16
US20100168036A1 (en) 2010-07-01
DK2134372T3 (en) 2016-06-06
PL2134372T3 (pl) 2016-09-30
EP2134372B1 (en) 2016-02-24
PL2481429T3 (pl) 2018-10-31
US20160243252A1 (en) 2016-08-25
EP2134372A2 (en) 2009-12-23
CY1120368T1 (el) 2019-07-10
JP2010523632A (ja) 2010-07-15
WO2008125800A3 (en) 2008-12-04
US20140179592A1 (en) 2014-06-26
ES2573228T3 (es) 2016-06-06
EP2481429A3 (en) 2013-07-03
EP2481428A2 (en) 2012-08-01
HK1258466A1 (en) 2019-11-15
ES2573682T3 (es) 2016-06-09
PT2481429T (pt) 2018-06-19
HRP20181043T1 (hr) 2018-09-21
US10556014B2 (en) 2020-02-11
WO2008125800A2 (en) 2008-10-23
LT2481429T (lt) 2018-09-10
SI2481429T1 (en) 2018-08-31
US8691751B2 (en) 2014-04-08
PL2481428T3 (pl) 2016-09-30
HUE038633T2 (hu) 2018-11-28
JP2016190848A (ja) 2016-11-10
EP2481428B1 (en) 2016-03-02
JP5931952B2 (ja) 2016-06-08
JP6170590B2 (ja) 2017-07-26
HK1174534A1 (en) 2013-06-14
JP5537413B2 (ja) 2014-07-02
JP2014193871A (ja) 2014-10-09
US9358303B2 (en) 2016-06-07
EP2481429A2 (en) 2012-08-01
HUE027528T2 (en) 2016-10-28
DK2481428T3 (en) 2016-06-13
DK2481429T3 (en) 2018-07-30
EP3348282A1 (en) 2018-07-18
US9956296B2 (en) 2018-05-01
EP2481429B1 (en) 2018-05-09
US20180228910A1 (en) 2018-08-16
TR201807811T4 (tr) 2018-06-21

Similar Documents

Publication Publication Date Title
GB0706793D0 (en) Compounds
GB0704407D0 (en) Compounds
GB0704394D0 (en) Compounds
GB0705672D0 (en) Compounds
GB0706173D0 (en) Compounds
GB0706168D0 (en) Compounds
GB0707092D0 (en) Compounds
GB0706188D0 (en) Compounds
GB0706165D0 (en) Compounds
GB0706174D0 (en) Compounds
GB0706187D0 (en) Compounds
GB0706189D0 (en) Compounds
GB0706167D0 (en) Compounds
GB0706170D0 (en) Compounds
GB0706164D0 (en) Compounds
GB0706190D0 (en) Compounds
GB0704939D0 (en) Compounds
GB0703756D0 (en) Compounds
GB0701955D0 (en) Compounds
GB0701985D0 (en) Compounds
GB0701956D0 (en) Compounds
GB0702973D0 (en) Compounds
GB0703906D0 (en) Compounds
GB0701984D0 (en) Compounds
GB0700283D0 (en) Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)